AI assistant
Anteris Technologies Global Corp. — Capital/Financing Update 2016
Aug 17, 2016
33869_rns_2016-08-17_4bbd289a-a40a-4c1a-9317-7d8f0ee9246e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [226 x 82] intentionally omitted <==
Admedus Ltd ABN 35 088 221 078
REGISTERED OFFICE: 26 Harris Road MalagaWestern Australia6090
COMPANY ANNOUNCEMENT
PO Box 6879 East Perth Western Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E [email protected]
ADMEDUS RENOUNCEABLE RIGHTS ISSUE NOW OPEN
Brisbane, Australia, 18 August 2016
Admedus Limited ( Admedus or Company ) (ASX: AHZ) announces today that its fully underwritten 1 for 9 Rights Issue to eligible shareholders to raise approximately $8.3 million opens today and will close at 3.00pm (WST) on 29 August 2016. In conjunction with the Rights Issue, Admedus recently completed a Placement of $10 million which ensures that the Company is in a strong financial position.
Admedus is focused on continued growth of sales across the company and is expecting at least a 50% growth in revenue in the 2017 financial year, along with expanding its near market product portfolio. Admedus is also well advanced in the restructuring and cost reduction initiatives announced to the market on 20 July 2016.
“The Board and I thank new and existing shareholders for their support as we direct the Company towards sustainability and continued growth. Admedus has great technologies and best in class products which we are leveraging to global commercial success as we continue to build a credible Australian global healthcare company,” said Mr Wayne Paterson, Chair and Interim CEO.
The prospectus and personalised entitlement and acceptance forms for the Rights Issue will be dispatched to eligible shareholders today and should be received in the next 3 days. Those eligible shareholders who have not received a prospectus and entitlement and acceptance form in that time frame should contact the Company via the details below. Eligible shareholders are also able to apply for additional shares in excess of their entitlement through the Rights Issue.
The closing price of the Company's shares on 9 August 2016 was 32.5c which is below the issue price for Rights Issue shares of 33c. Whilst this triggers a termination right, as disclosed in the Prospectus dated 2 August 2016, we note that the closing price of the Company shares on 17 August was $0.335 and the Rights Issue continues to be fully underwritten by Patersons Securities Limited.
Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com Blog: www.admedus.com/au/category/news/
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Media :
Shevaun Cooper | PR Manager | Admedus Limited
==> picture [595 x 44] intentionally omitted <==
==> picture [170 x 63] intentionally omitted <==
Tel: +61 (0) 417 985 599 | Email: [email protected]
Media Europe
FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 [email protected]
US Investor
Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 [email protected]
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the Company can be found on www.admedus.com.